06 May 2020

Ulbrich & Partner supported on the sale of Provecs lab to Centogene


Ulbrich&Partner supported White & Case partner Dr. Sven-Holger Undritz in his capacity as insolvency administrator of Provecs Medical GmbH on the sale of the laboratory to Centogene AG.


Here is what White & Case said:

Hamburg – White & Case Partner Dr. Sven-Holger Undritz hat in seiner Eigenschaft als Insolvenzverwalter die Laboreinrichtung und -geräte der Provecs Medical GmbH (Provecs) an die CENTOGENE AG (CENTOGENE) veräußert. Auch nach der Stellung des Insolvenzantrags am 25.9.2019 beim Amtsgericht Hamburg wurde die Forschungs- und Entwicklungsarbeit der Provecs im Bereich neuartiger Immuntherapeutika für die Behandlung von Krebs zunächst vollumfänglich fortgeführt. Das Provecs-Team hat eine patentierte Plattformtechnologie entwickelt, die mit Hilfe optimierter Erkältungsviren (Adenoviren) Informationen in das Krebsgewebe bringen. Durch die rasante Ausbreitung der COVID-19-Pandemie verlagerte sich der Schwerpunkt des ursprünglich auf die patentierte Plattformtechnologie ausgerichteten Investorenprozesses, der von der auf die Biotech-Branche spezialisierten Unternehmensberatung Ulbrich & Partner aus Hannover begleitet wurde, schnell hin zu der Laboreinrichtung der Provecs, die teilweise auch für die COVID-19-Diagnostik einsatzfähig ist. Per sofort übernimmt CENTOGENE Laboreinrichtung und -geräte der Provecs an deren bisherigem Standort in Hamburg. Damit soll kurzfristig zunächst eine erhöhte Testkapazität für das COVID-19-Virus ermöglicht und darüber hinaus eine Erweiterung der Laborkapazitäten für die diagnostischen Tests auf seltene genetische Krankheiten geschaffen werden.

„Aufgrund der aktuellen Situation rund um die COVID-19-Pandemie bin ich sehr froh, dass wir aus dem Insolvenzverfahren heraus die Laborkapazitäten der Provecs zügig an CENTOGENE übertragen konnten“, kommentierte Insolvenzverwalter Dr. Sven-Holger Undritz die Transaktion.

CENTOGENE, mit Hauptsitz in Rostock, ist eines der weltweit größten Gentechnologie- und Biotech-Unternehmen und ein führender Anbieter von genetischen diagnostischen Analysen seltener Erbkrankheiten.

Zum White & Case Team um Partner Dr. Sven-Holger Undritz gehörten die Local Partner Dr. Ellen Meyer-Sommer und Béla Knof (alle Insolvenz/Restrukturierung, Hamburg). Unterstützt wird der Insolvenzverwalter von der auf die Biotech-Brache spezialisierten Unternehmensberatung Ulbrich & Partner aus Hannover.

For more details please follow the link:

04 July 2019

ulbrich&partner advises MODAG on €12 million Series A Financing and accompanying acquisition of a further substance license

ulbrich&partner adviced MODAG on the in-licensing of novel chemical IP and on closing of a € 12 million Series A financing round


Hanover, June 28, 2019 – ulbrich&partner advised the German biotech company MODAG on the in-licensing of novel chemical IP from Max Planck Innovation GmbH extending its compound portfolio targeting neurodegenerative diseases and on the closing of a € 12 million Series A financing round, led by the Massa Investment AG, Switzerland.

ulbrich&partner supported MODAG in business planning as well as advised on the structuring and operational implementation of the in-licensing of the active substance as well as the series A financing.

"With our long-term transaction experience and the sound know-how in financial and business planning we have been able to make a valuable contribution in this exciting Series A Financing as well as with regard to the in-licensing," comments Dr. Claudia Ulbrich, managing partner at ulbrich&partner in Hanover.

The MODAG GmbH, located at the high-technology park in Wendelsheim, Germany, deals with the research and development of therapeutics and diagnostics for neurodegenerative diseases. MODAG GmbH’s innovative approach offers a unique combination of early diagnosis and targeted disease modifying therapies.

Max Planck Innovation is responsible for the technology transfer of the Max Planck Society and, as such, serves as a link between industry and basic research. With its interdisciplinary team, it advises and supports scientists in evaluating their inventions, filing patents, and founding companies.

The team of ulbrich&partner advises regularly pharmaceutical and young biotech companies on business development and financing healthcare transactions.

Advisor to MODAG GmbH:


Lead: Dr. Claudia Ulbrich (Managing Partner, Hanover)

Team: Andreas Kranzusch (Senior Consultant, Freiburg)

About ulbrich&partner:

ulbrich&partner Management Consulting is specializing in strategic and business consultancy with a focus on pharmaceutical, life science and health care technologies. As a team of experienced entrepreneurs and consultants along with a network of seasoned international experts u&p is ideally suited to provide with state-of-the-art solutions for consulting needs regarding structuring spin-offs, start-up funding and partnering & exit strategies.

ulbrich&partner is a management consultancy specialized in the high-tech & life science sector with special knowledge in the areas of consulting and the creation of business concepts, financing consulting including public funds, the filling of interim or management and corporate service positions as well as international business development, change management and transaction business.

Contact: Vanessa Krukenberg Tel. 0511-37484051 / 0177-4634784

03 July 2019

Science4Life Venture Cup 2019 - 3rd place for u&p coached team Ycor


The founders team of Ycor reached the 3rd place in the Science4Life Venture Cup 2019.

The Ycor team has been coached by Dr. Claudia Ulbrich, founding partner of ulbrich&partner management consulting. The winner teams of this year’s Science4Lfe Venture Cup are presented here:

26 April 2018

ulbrich&partner moderates panel at seminar “Investing in Biotech in Europe from Seed to Exit: Latest Trends”

Baker McKenzie, a Munich based law-firm hosts this event with a number of high-class speakers and presentors.


During the seminar topics will be handled as:

  • Pitfalls when launching a biotech venture out of university, in-licensing IP and know-how from the tech transfer office, suitable deal terms with institutional VC investors, managing the conflict of interest of the spin-off as a university scientist and shareholder of the venture business.
  • Accelerated exit by an structured M&A deal with big pharma – taking advantage of crossover financing – managing multiple tracks to secure funding – seamless work streams towards IPO or trade sale.

For further insights into the program please follow to this link:

26 June 2017

Science4Life Venture Cup 2017 - Final Competition

ulbrich&partner coached the winner team aidcure


12 June 2017

ulbrich&partner event schedule: Family Day 2017 (30.05-31.05)

ulbrich&partner participated in Family Day Hightech Gründerfonds, 30/31 May 2017 in Bonn and was moderator of 2 investors panels.


11 May 2017

Cardior Pharmaceuticals closed successfully a Series A round with €15 million Venture Capital

ulbrich&partner acted as business advisor to the founders and company.


12 January 2017

ulbrich&partner event schedule: Family Day 2016 (31.05-01.06)

ulbrich&partner participates in Family Day Hightech Gründerfonds, 23/24 June 2015 in Bonn.


11 July 2016

Science4Life Venture Cup 2016 - Final Competition

ulbrich&partner coached team SpinDiag GmbH.


09 March 2016

ulbrich&partner launches cooperation with SmartStep

SmartStep is a consulting firm specialized in the field of health care.


The firm provides market access consultation and other services related to health care with a focus on market access consulting for pharmaceutical and medical device companies. It also initiates, implements, accompanies and evaluates all measures that are used to translate its market access consulting solutions into practice.

To the SmartStep homepage

Page 1 of 2 Next


ulbrich&partner management consulting
Claudia Ulbrich MD
Güntherstraße 7A | 30519 Hannover | Germany | Mobile +49 (0) 172 / 455 76 32
Phone +49 (0) 511 / 37 48 40 51
Geschäftsführung: Dr. Claudia Ulbrich

1. Content
The author reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. All offers are not-binding and without obligation. Parts of the pages or the complete publication including all offers and information might be extended, changed or partly or completely deleted by the author without separate announcement.

2. Referrals and links
The author is not responsible for any contents linked or referred to from his pages - unless he has full knowledge of illegal contents and would be able to prevent the visitors of his site from viewing those pages. If any damage occurs by the use of information presented there, only the author of the respective pages might be liable, not the one who has linked to these pages. Furthermore the author is not liable for any postings or messages published by users of discussion boards, guestbooks or mailing lists provided on his page.

3. Copyright
The author intended not to use any copyrighted material for the publication or, if not possible, to indicate the copyright of the respective object. The copyright for any material created by the author is reserved. Any duplication or use of objects such as images, diagrams, sounds or texts in other electronic or printed publications is not permitted without the author's agreement.

4. Privacy policy
If the opportunity for the input of personal or business data (email addresses, name, addresses) is given, the input of these data takes place voluntarily. The use and payment of all offered services are permitted - if and so far technically possible and reasonable - without specification of any personal data or under specification of anonymized data or an alias. The use of published postal addresses, telephone or fax numbers and email addresses for marketing purposes is prohibited, offenders sending unwanted spam messages will be punished.

5. Legal validity of this disclaimer
This disclaimer is to be regarded as part of the internet publication which you were referred from. If sections or individual terms of this statement are not legal or correct, the content or validity of the other parts remain uninfluenced by this fact.